

■ **Interleukin-4-38-37-PE38KDEL gains orphan drug status** in the EU. The agent, developed by Protox Therapeutics, has received the designation from the European Commission for the treatment of glioma.

Protox Therapeutics Inc. Protox granted orphan status in Europe for brain cancer treatment. Media Release : 17 Jun 2008. Available from: URL: <http://www.protoxtherapeutics.com> 809090240